Vaccine team aims at ending ear, sinus infections

A team of researchers is preparing to begin trials of a new vaccine that is designed to eliminate childhood ear and sinus infections. Lead investigator Dr. Michael Pichichero, a professor of microbiology, immunology, pediatrics, and medicine at the University of Rochester Medical Center, says their effort marks a departure from most vaccine programs, which are typically focused on saving lives. In this case, the researchers are devoting themselves to eliminating common ailments. Their vaccine is aimed at Nontypeable Haemophilus influenzae, which is now the primary cause of bronchitis and ear and sinus infections. While these conditions are typically not life-threatening, they can cause serious physical damage and can tie up hospital emergency rooms in the flu season. Using funding from the National Institute of Deafness and Communication Disorders, they will begin testing a vaccine that uses parts of the bacteria to stimulate an immune response.

- here's the article on the vaccine project from The Washington Post

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.